

Author Index

- A**
Adelman, Karen, 253
Aderounmu, Adedeji M., 185
Aguilera, Andrés, 105, 256
Aral, Chie, 115
- B**
Bartel, David, 259
Basquin, Jérôme, 155
Bass, Brenda L., 185
Benda, Christian, 155
Biswas, Jeetayu, 1
Bonneau, Fabien, 155
Borges, Filipe, 133
- C**
Cai, Zhiqiang, 115
Carrocci, Tucker J., 11
Chang, Howard Y., 31
Chen, Jia-Yu, 55
Chen, Ling-Ling, 67, 262
Cho, Hana, 47
Conti, Elena, 155
Corbet, Giulia Ada, 203
- D**
Das, Sulagna, 1
Dean, Caroline, 264
Di, Chao, 115
Donelick, Helen M., 185
Doudna, Jennifer, 245
Dreyfuss, Gideon, 115, 239
Duan, Jingqi, 115
- E**
Eliscovich, Carolina, 1
- F**
Falk, Sebastian, 155
Fazal, Furqan M., 31
Fu, Xiang-Dong, 55
- G**
Gaidatzis, Dimos, 141
Gasser, Susan M., 141, 266
Gerlach, Piotr, 155
Gross, John D., 217
- H**
Hansen, Sarah R., 185
Hezroni, Hadas, 165
Hirose, Tetsuro, 227
- J**
Jaffrey, Samie, 268
Joshua-Tor, Leemor, 271
- K**
Kalck, Véronique, 141
Kornbliht, Alberto, 274
Kraimer, Adrian, 276
- L**
Lim, Do-Hwan, 55
Lingaraju, Mahesh, 155
Liu, Chu-Xiao, 67
Luna, Rosa, 105
Lynch, Kristen W., 123
- M**
MacRae, Ian J., 179
Mao, Steve, 262, 302
- N**
Maquat, Lynne E., 47, 279
Martienssen, Robert A., 133
Mattout, Anna, 141
Mayr, Christine, 95
- N**
Nakagawa, Shinichi, 227
Narlikar, Geeta J., 217
Neugebauer, Karla M.,
11, 282
Nunez, Leti, 1
- P**
Parent, Jean-Sebastien, 133
Parker, Roy, 203
Passmore, Lori A., 21
Pawlica, Paulina, 179
Pérez-Calero, Carmen, 105
Perry, Rotem Ben Tov, 165
Pikaard, Craig S., 195
Proudfoot, Nicholas, 285
- R**
Rambout, Xavier, 47
Rando, Oliver, 288
Rondón, Ana G., 105
- S**
Salas-Armenteros, Irene, 105
Sanulli, Serena, 217
Schuller, Jan M., 155
Sever, Richard, 259, 279, 285
Sharp, Phillip, 291
Sheu-Gruttadauria, Jessica, 179
Shimada, Atsushi, 133
Singer, Robert H., 1
Singh, Jasleen, 195
- So, Byung Ran, 115, 239**
Sparmann, Anke, 268, 276,
294, 296
Steitz, Joan A., 179
Szewczak, Lara, 256, 271
- T**
Tang, Terence T.L., 21
Tatomer, Deirdre C., 83
Thompson, Matthew G., 123
Torres-Padilla Maria-Elena,
294
- U**
Ulitsky, Igor, 165, 296
- W**
Weldon, Carika, 274, 282,
288, 291
Wilusz, Jeremy E., 83, 299
Witkowski, Jan, 253, 264,
266, 299
- Y**
Yamazaki, Tomohiro, 227
Yao, Run-Wen, 67
Yoon, Young J., 1
- Z**
Zhang, Feng, 302

Subject Index

A

Actin, 240
ADAR, 185, 303
ADAR1, 71
Ago. *See* Argonaute
AGO4, 135, 195, 198–199
AGO6, 135
AGO9, 135
ALKBH5, 269
ALN, 136
ALS. *See* Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), 203
ANKRD52, 68
APC, 32
APEX, 6–7, 37–38, 40, 203, 228
AQR, 110
Architectural RNA (arcRNA)
 NEAT1_2
 biogenesis, 229–230
 functional RNA domains,
 230–232
 phase-separated paraspeckle nuclear
 body formation
 characteristics, 228–229
 mechanisms, 232
 overview, 227–228
 prospects for study, 232–234
 arcRNA. *See* Architectural RNA
Argonaute (Ago), 179–181, 267
ASH1, 3, 35
Asterix, 271

B

BACE1, 173
BBP, 12
BDNF, 173
BIRC3, 97–98
BLM, 110
BRCA, 257
BRCA1, 110
BRCA2, 258

C

Caenorhabditis elegans. *See* LSM proteins
Caf1, 22, 27–28
Cap-binding complex (CBC), 15, 47–48
CAPRIN1, 100–101
CAST, 302
CBC. *See* Cap-binding complex
CBP/p300, 48
CBP20, 47, 280
CBP80, 280
 functional overview, 47–48
 PGC-1 interactions, 48–53

CCAT1-L, 67
CCR5, 249
CD47, 97, 99–101
CDAR, 303
CDK12, 120
CDK9, 59
CFIm25, 118–120
CFIm59, 120
CFIm68, 118, 120
ChIP-seq, 56
Chromatin
 RNA-binding proteins
 detection, 56–57
 functional impact on gene
 expression, 57–58
 heterochromatin formation,
 spreading, and maintenance,
 59–60
 promoters as hotspots for actions,
 58–59
 RNA polymerase II interactions, 58
 three-dimensional genome
 organization, 61–62
 RNA splicing interactions, 15–16
 transcription connection to downstream
 RNA metabolism events, 60

Circular RNA

 biogenesis, 70–71
 identification of types, 68–70
 innate immunity regulation, 70–71
 localization study prospects, 41
 overview, 299

CLIP, RNA-binding protein
 studies, 6, 14, 57

CLK1, 128
CLN3, 210
CLSY, 134, 199
CMT3, 198
CNOT6L, 22
CNOT7, 100–101
CPSE, 119, 254
CRISPR, 56, 73–74, 76, 145, 166, 171,
 234, 245–249, 263, 283,
 287, 296, 302

CRNDE, 173
Csl4, 156
CstF, 119
CstF64, 119
CTCF, 61
CXCR4, 97
Cyrano, 168

D

Dali, 168
DAZAP1, 230

DCL proteins, 133–134
DCL3, 195–198
DDMI, 134
DDX1, 110
DDX5, 110
DDX19, 110–111
DDX19A, 208
DDX21, 59, 73–74, 76, 110–111
DDX23, 110–111
DDX39A, 109
DDX39B, 109
Deadenylation. *See* Poly(A) tail
DGCR5, 173
DHX9, 110
Dicer
 double-stranded RNA-binding
 protein modulation
 of function
 Loquacious, 190
 R2D2, 190–191
 RNase III enzymes, 187–189
 TBRP, 189–190
 functional overview, 185
 helicase domain
 prospects for study, 191
 vertebrate versus invertebrate
 functions, 186–187

DIS3, 156
DIS3L, 156
DMS3, 136
DNMT1, 59
DNMT3a, 196
DNMT3b, 196
DOGL4, 136
Dorcas Cummings Lecture, 245–250
DRD1, 136, 199
DRM2, 136, 196
DSIF, 59

E

Edc3, 205
EGFP, 71
Egr2, 172
eIF4A, 208
eIF4E, 280
EJC. *See* Exon junction complex
EMCV. *See* Encephalomyocarditis virus
Encephalomyocarditis virus (EMCV), 71
Eyf2, 168
Exo9, 156–157
Exo10, 157
Exo13, 157, 160
Exo13n, 157
Exo14n, 157
Exon junction complex (EJC), 279–280
Exosome. *See* RNA exosome

- F**
- FAM, 303–304
FANCM, 110
far-3, 150
FBL, 76–77
Fip1, 119
Firre, 40, 61
FIS2, 137
FLC, 264
FMRP, 32
Frontotemporal lobar degeneration (FTLD), 203
FTLD. *See* Frontotemporal lobar degeneration
FUBP3, 6
FUS, 229–231
- G**
- G3BP1, 205, 208, 210
GAS5, 173
Granules. *See* Ribonucleoprotein granule *grl-23*, 150
- H**
- Hand2as*, 167
HDA6, 196
HDAC. *See* Histone deacetylase
Heterochromatin. *See* HP1
Histone deacetylase (HDAC), RNA splicing studies, 16
Histone methylation, LSM proteins in heterochromatin silencing, 145–150
HiTS, RNA-binding protein studies, 6
HNRNPA1, 58–59, 231, 274–275
HNRNPA2, 274–275
HNRNPH3, 230
HNRNPK, 229, 298
HNRNPLL, 58
HNRNPU, 33
HP1
heterochromatin
assembly modeling
nucleosome engagement, 222
octamer deformation, 222
oligomers versus dimers, 222
phase separation, 222–223
chromatin interactions, 219
features, 217
histone core disorganization and chromatin compaction into droplets, 220–222
oligomerization behavior, 218–219
phase separation, 219–220
Hpr1. *See* THO complex
HSUR1, 179, 182
- I**
- IDN2, 135
IGF2BP1. *See* ZBP1
Influenza A virus
genome, 123
- NS1, 123, 125–130
NS2, 123, 125
RNA splicing
host splicing regulation by infection, 127–128
isoforms, 124–125
M segment splicing regulation, 125–127
prospects for study, 128–130
Integrator
development role, 88
eukaryote distribution, 88
metallothionein A transcription regulation
cleavage of transcripts, 85–86
RNA interference screening, 84–85
non-MtnA targets of, 87
small nuclear RNA cleavage, 253–255, 301
specialized subcomplexes, 88
ITS2, 158, 160
- J**
- JmjC, 196
- K**
- KLF4, 173
- L**
- LINE, 294
lncRNA. *See* Long noncoding RNA
Long noncoding RNA (lncRNA). *See also* Architectural RNA
classes, 285
functional overview, 165, 296–297
nervous system studies
conceptual roles, 174
development functions, 167–171
differential expression, 165–166
neurological diseases, 173–174
neuroregeneration role, 171
peripheral nerve injury, 171–172
spinal cord injury, 172–173
subcellular expression, 166
techniques for study, 166–167
traumatic brain injury, 173
snoRNA-ended long noncoding RNA
identification, 71–73
Prader–Willi syndrome role, 73
SLERT, 73–74
Loquacious, 190
LSM proteins
H3K27me3 level maintenance, 150
heterochromatic reporter silencing, 144–145
mRNA reduction from heterochromatic reporters, 141, 143
overview, 141–142, 267
polycomb-marked gene targeting, 146–148, 150
prospects for study, 150–151
RNA degradation and silencing
enzymes in RNA degradation, 148–150
overview, 148
silent endogenous heterochromatin maintenance, 145, 147
- M**
- m⁶A, 268–270
MALAT1, 33, 67–68, 83–84, 173, 241
Massively parallel reporter assay (MPRA), 39
MB1. *See* THO complex
MEDEA, 137
MEG3, 173
MEG-3, 210
Megamind, 168
Meganuclease, 246
MERFISH, 36
MES-2, 151
MET1, 198
Methallothionein A (MtnA), integrator complex in transcription regulation
cleavage of transcripts, 85–86
non-MtnA targets of integrator complex, 87
RNA interference screening, 84–85
Methylated adenosine. *See* m⁶A
Mex67, 106
Miat, 173
MicroRNA (miRNA)
functional overview, 179, 259–261
knockdown, 259
RNA-induced silencing complex, 283
target-directed microRNA degradation mechanisms, 180–181
overview, 179–180
prospects for study, 181–182
miRNA. *See* MicroRNA
Mitochondria, RNA localization, 40–41
Mpp6, 157–158
MPRA. *See* Massively parallel reporter assay
MTF-1, 87
MtnA. *See* Methallothionein A
Mtr4, 157–158, 160
MTREC, 88
Mud2, 12
- N**
- Nab3, 88
NEAT1, 67–68, 77, 83, 173, 207, 230–232, 262
NEAT1_2. *See* Architectural RNA
NELF, 59
NF110, 71
NMD. *See* Nonsense-mediated decay
NONO, 229–231
Nonsense-mediated decay (NMD), 279–281
Nop53, 159
NORAD, 67, 210
NPC. *See* Nuclear pore complex

- Nrd1, 88
NS1, 123, 125–130
NS2, 123, 125
Nuclear pore complex (NPC), 34
Nucleolus. *See also* Small nucleolar RNA
ultrastructure, 74–76
NUP160, 50
- P**
- P4R2, 198
PABP-2, 151–152
PABPC1, 21
Pan2, 22–25
Pan3, 22–23
Pantr2, 168
PARN, 182
pax6, 168
PCF11, 88
PCPA, 116–118, 120, 240
Peripheral nerve injury (PNI), long
noncoding RNA studies,
171–172
- PGC-1 α
CBP80 interactions, 48–53
RNA accumulation prevention, 50–51
target gene transcription, 48–49
- PGC-1 β , 48
Pif1, 110
PINK1, 173–174
piRNA. *See* Piwi-interacting RNA
Piwi-interacting RNA (piRNA), 271,
288–289
- PKR, 71, 262–263
PKR185
- Plant small RNA
chromatin reprogramming, 134–136
generation, 133–134
germline functions, 136–137
- PNI. *See* Peripheral nerve injury
- Poly(A) tail
deadenylation
Caf1, 22, 27–28
exonuclease specificity, 22
tail recognition
adenine modification studies,
26–27
deadenylase complexes, 21–22
Pan2, 23–25
tail structure importance, 24–25
intrinsic structure, 23–24
non-A sequences, 22–23
overview, 21
translation role, 28
- Polycomb, 265–266
POU3F3, 168, 171
PPIP5K2, 128
Prader–Willi syndrome (PWS), 73
PRC1, 59
PRC2, 59–60
PRDM5, 173
Pre-mRNA, processing, 239–240
P-TEFb, 48, 59
PTEN, 98
Puf3, 33–34
PWS. *See* Prader–Willi syndrome
- R**
- R2D2, 190–191
RAB1, 128
RAG, 171
Rasa1, 173
RBFox2, 73
RBM14, 229, 231
RBP-12, 151–152
RBP-7, 151–152
RdDM. *See* RNA-directed DNA
methylation
- RDM1, 136
RDR2, 133, 195–199
REPAIR system, 303
RESCUE system, 303
REXQ5, 110
- Ribonucleoprotein granule
composition
proteins, 203, 205–206
RNA, 206–207
formation, 207–208
functional overview, 203–205
ribonucleoprotein
partitioning into stress granules
and P-bodies, 209–210
recruitment, 208–209
self-assembly, 240–241
sorting between multiple granule
types, 210
- Ribosomal RNA (rRNA)
RNA exosome in processing
mechanism, 159–161
role, 158–159
translocation and processing, 76–77
- R-loop, 107–111, 256–258, 286
RMST, 168
RNA-binding proteins. *See also specific
proteins*
functional overview, 240
- RNA-directed DNA methylation (RdDM)
overview of components, 195–196
prospects for study, 197–199
studies
in vitro, 197–199
in vivo, 196–197
- RNA exosome
core complex, 155–156
mechanism of RNA decay, 158
nuclear cofactors, 157–158
overview, 155
ribosomal RNA processing
mechanism, 159–161
role, 158–159
- RNA localization
history of study, 31–32
mechanisms
active transport, 34
cis element role, 32–33
overview, 2
RNA-binding proteins, 33–34
splicing, intron retention, and
nuclear export, 34–35
prospects for study
contribution of translation-
dependent localization
versus RNA-dependent
localization, 39–40
non-mRNA localization, 41
organelle RNA localization, 40–41
RNA influence on genome
architecture, 40
RNA modifications and
structure, 40
techniques for study
imaging, 35–36
machine learning, 38–39
massively parallel reporter
assays, 39
proximity labeling, 37–38
sequencing
next generation sequencing, 39
transcriptome-wide sequencing,
36–37
single RNA tracking, 35
ZBP1 and β -actin messenger RNA
localization, 2–3
- RNA polymerase II
carboxy-terminal domain modifica-
tions, 14–15
cotranscriptional RNA processing, 240
cotranscriptional spliceosome
assembly, 14
RNA-binding protein interactions, 58
transcription connection to downstream
RNA metabolism, 60
- RNA polymerase IV, 195–199
RNA polymerase V, 195, 199
RNase A, 256
RNase H, 256
RNase III, 187–189
RNA splicing
chromatin interactions, 15–16
influenza infection. *See* Influenza
A virus
mechanism, 12–13
nuclear landscape, 16, 34–35
overview, 11
RNA capping, 15
spliceosome
assembly, 13–14
RNA polymerase II modification
impact, 14–15
- rRNA. *See* Ribosomal RNA
Rrp4, 156, 158
Rrp6, 157–160
RRP6L1, 199
Rrp40, 156
Rrp44, 156–160
Rrp47, 157
- S**
- SAHA, 109
SCI. *See* Spinal cord injury
SDC, 137
SECRET sequence, 33
Sen1, 88, 109–110
SeqFISH, 36
SET, 100–101
SETX, 109–110
SFPQ, 229, 231

- SHERLOCK system, 303
SHH1, 134
SHH2a, 198
SHH2b, 198
Sin3A, 109
SIRLOIN, 39
SIRT7, 68
SIX3, 168
SLE. *See* Systemic lupus erythematosus
SLERT, 73–74
SMA. *See* Spinal muscle atrophy
Small nucleolar RNA (snoRNA), snoRNA-
ended long noncoding RNA
 identification, 71–73
 Prader–Willi syndrome role, 73
 SLERT, 73–74
SMG1, 47, 280
SMN, 242, 274
SMN1, 274, 276
SMN2, 274–276
SNHG5, 173
snoRNA. *See* Small nucleolar RNA
SOX2, 168
SP4, 67–68, 73
Spinal cord injury (SCI), long noncoding
 RNA studies, 172–173
Spinal muscle atrophy (SMA), 242,
 263, 274–277
SPINRAZA, 263, 276–277
Spliceosome. *See* RNA splicing
Spp381, 108
SPT5L, 195
SPT6, 287
Staufen, 33–34
Staufen-mediated mRNA decay, 280
Sub2, 106, 108–109, 111
SUV39, 60
SUVH, 196, 198
SUVH2, 136
SUVH9, 136
SWI/SNF, 196, 222, 229–230
Swi6, 219
Systemic lupus erythematosus (SLE), 262
- T**
- T1S11B, 99–100
TALEN, 246
Target-directed microRNA degradation.
 See MicroRNA
TBI. *See* Traumatic brain injury
TBRP, 187, 189–190
TDP-43, 32, 73, 231
- Telescripting. *See* U1
TENT4A, 23
TENT4B, 23
TET1, 59
Tex1. *See* THO complex
THO complex
 chromatin distribution, 106
 components, 105
 cotranscriptional role in chromatin,
 108–109
 R-loop prevention
 overview, 107–108
 RNA helicase role, 109–111
 structure, 106
 UAP56 role in ribonucleoprotein
 biogenesis, 109
Tho2. *See* THO complex
Thp2. *See* THO complex
THZ531, 120
TIA-1, 210
TNRC6, 260
TORC1, 70
TP53, 98
Traumatic brain injury (TBI), long
 noncoding RNA studies, 173
TREX, 35, 106, 120
TRIBE, RNA-binding protein studies, 6
TSA, 109
TUNA, 173
TUT1, 181
TUT4, 181–182
TUT7, 182
- U**
- U1
 inhibition of premature RNA
 cleavage, 89–90
 recruitment in influenza A virus
 RNA splicing, 126
 telescripting
 biological roles
 long intron telescripting and
 gene regulation, 118
 promoter directionality, 117
 short mRNA isoform switching,
 cell stimulation, and
 oncogenicity, 117–118
 transcriptome control and
 proteome diversification,
 116–117
 mechanisms, 118–120
 overview, 115–116
- U2, 239, 242
U4, 239
U5, 239
U6, 239, 266
UAP56, 106, 108–109, 111, 257–258
UBAP21, 208
3'-Untranslated region
 protein function regulation
 discovery, 97
 mass spectrometry studies, 97–98
 mechanisms, 99–100
 overview, 95
 protein activity versus
 abundance, 98
 shortening effects on transcript levels,
 95–96
UPF proteins, 47, 279–280
URH49, 109
UTPa, 76
UTPb, 76
- V**
- Valproic acid (VPA), 275
VPA. *See* Valproic acid
- X**
- XIST, 230
XRN1, 144, 151, 266
XRN2, 73, 151–152, 266
- Y**
- YB-1, 205
Ym1, 106
YTH proteins, 269–270
YTHDC1, 40
YTHDF, 40
YY1, 61, 172
- Z**
- ZBP1, 240
 dendrite RNA transport, 4–5
 imaging studies, 7
 prospects for study, 7–8
 β-actin messenger RNA
 localization, 2–3, 32
 translation control, 3
ZFN, 246
ZK970.2, 150